 |
| Fletcher, CC BY 4.0, via Wikimedia Commons Fletcher |
Moderna Inc reported a profit of 19 cents per share on Thursday. This trashed their expectation of a gross loss. Due to their deferred COVID-19 vaccine supplies.
They booked more revenue than in the first quarter of last year. This vaccine maker reported a profit of 19 cents per share.
Moderna is also aware of the falling demand for COVID-19 vaccine sales. They are expecting a loss in COVID-19 vaccine sales next quarter.
Moderna’s annual sales may go up as the new vaccination season begins. They have many contracts and upcoming contracts to be signed in the U.S. before the upcoming vaccination season.
